Cargando…

Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs

PURPOSE: To show the impact of drug–drug interactions (DDIs) associated with co-administration of enzyme-inducing (EI) antiseizure medications and oral contraceptives (OCs) on the annual number of unintended pregnancies, their outcomes, and their associated costs in the United States (US). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Seri, Mauskopf, Josephine, Talbird, Sandra E., White, Annesha, Srinivasan, Meenakshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683747/
https://www.ncbi.nlm.nih.gov/pubmed/34775242
http://dx.doi.org/10.1016/j.yebeh.2021.108368
_version_ 1784617482570432512
author Anderson, Seri
Mauskopf, Josephine
Talbird, Sandra E.
White, Annesha
Srinivasan, Meenakshi
author_facet Anderson, Seri
Mauskopf, Josephine
Talbird, Sandra E.
White, Annesha
Srinivasan, Meenakshi
author_sort Anderson, Seri
collection PubMed
description PURPOSE: To show the impact of drug–drug interactions (DDIs) associated with co-administration of enzyme-inducing (EI) antiseizure medications and oral contraceptives (OCs) on the annual number of unintended pregnancies, their outcomes, and their associated costs in the United States (US). METHODS: A Microsoft Excel pregnancy-outcomes model was developed to determine the impact of DDIs in women who take an OC as well as an EI antiseizure medication known to lower the effectiveness of the OC in preventing pregnancy. The model compared the number of unintended pregnancies, the expected pregnancy outcomes, and associated costs in women taking an OC and an EI medication with a matched cohort of women who took an OC and an enzyme-neutral (EN) antiseizure medication that is known not to interact with OCs. The model perspectives were patients and third-party payers in the US. Unintended pregnancy rates, pregnancy outcomes, and cost inputs for the model were taken from published studies. RESULTS: The results of the analysis showed an estimated increase in the annual number of unintended pregnancies in the US of 503 (a change from 1151 to 1654), an increase of 44.7%, for the estimated 71,922 women currently taking an OC plus an EI medication in the US when compared with a matched cohort taking an OC plus an EN medication. This resulted in an estimated annual healthcare cost increase of $3 million, which is an increase of 5.5% in the annual costs for contraception and pregnancy care. A scenario analysis showed that the annual number of unintended pregnancies could be lower (575 vs 1654) for a matched cohort of women taking EI medications and using a copper intrauterine device, a highly effective and nonhormonal form of contraception, rather than an OC. CONCLUSIONS: Physicians treating women of reproductive age for epilepsy who wish to avoid pregnancy should consider the potential for DDIs that might result in unintended pregnancies. Thus, physicians should alert women using EI medications for epilepsy control to the increased potential for unintended pregnancies if they use OCs for contraception.
format Online
Article
Text
id pubmed-8683747
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Academic Press
record_format MEDLINE/PubMed
spelling pubmed-86837472021-12-30 Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs Anderson, Seri Mauskopf, Josephine Talbird, Sandra E. White, Annesha Srinivasan, Meenakshi Epilepsy Behav Article PURPOSE: To show the impact of drug–drug interactions (DDIs) associated with co-administration of enzyme-inducing (EI) antiseizure medications and oral contraceptives (OCs) on the annual number of unintended pregnancies, their outcomes, and their associated costs in the United States (US). METHODS: A Microsoft Excel pregnancy-outcomes model was developed to determine the impact of DDIs in women who take an OC as well as an EI antiseizure medication known to lower the effectiveness of the OC in preventing pregnancy. The model compared the number of unintended pregnancies, the expected pregnancy outcomes, and associated costs in women taking an OC and an EI medication with a matched cohort of women who took an OC and an enzyme-neutral (EN) antiseizure medication that is known not to interact with OCs. The model perspectives were patients and third-party payers in the US. Unintended pregnancy rates, pregnancy outcomes, and cost inputs for the model were taken from published studies. RESULTS: The results of the analysis showed an estimated increase in the annual number of unintended pregnancies in the US of 503 (a change from 1151 to 1654), an increase of 44.7%, for the estimated 71,922 women currently taking an OC plus an EI medication in the US when compared with a matched cohort taking an OC plus an EN medication. This resulted in an estimated annual healthcare cost increase of $3 million, which is an increase of 5.5% in the annual costs for contraception and pregnancy care. A scenario analysis showed that the annual number of unintended pregnancies could be lower (575 vs 1654) for a matched cohort of women taking EI medications and using a copper intrauterine device, a highly effective and nonhormonal form of contraception, rather than an OC. CONCLUSIONS: Physicians treating women of reproductive age for epilepsy who wish to avoid pregnancy should consider the potential for DDIs that might result in unintended pregnancies. Thus, physicians should alert women using EI medications for epilepsy control to the increased potential for unintended pregnancies if they use OCs for contraception. Academic Press 2021-12 /pmc/articles/PMC8683747/ /pubmed/34775242 http://dx.doi.org/10.1016/j.yebeh.2021.108368 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anderson, Seri
Mauskopf, Josephine
Talbird, Sandra E.
White, Annesha
Srinivasan, Meenakshi
Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
title Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
title_full Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
title_fullStr Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
title_full_unstemmed Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
title_short Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
title_sort antiseizure medications and oral contraceptives: impact of enzyme inducers on pregnancy outcomes and costs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683747/
https://www.ncbi.nlm.nih.gov/pubmed/34775242
http://dx.doi.org/10.1016/j.yebeh.2021.108368
work_keys_str_mv AT andersonseri antiseizuremedicationsandoralcontraceptivesimpactofenzymeinducersonpregnancyoutcomesandcosts
AT mauskopfjosephine antiseizuremedicationsandoralcontraceptivesimpactofenzymeinducersonpregnancyoutcomesandcosts
AT talbirdsandrae antiseizuremedicationsandoralcontraceptivesimpactofenzymeinducersonpregnancyoutcomesandcosts
AT whiteannesha antiseizuremedicationsandoralcontraceptivesimpactofenzymeinducersonpregnancyoutcomesandcosts
AT srinivasanmeenakshi antiseizuremedicationsandoralcontraceptivesimpactofenzymeinducersonpregnancyoutcomesandcosts